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Abstract
Background Cancer wasting is characterized by muscle loss and may contribute to fatigue and poor quality of life (QoL). Our
aim was to investigate associations between skeletal muscle index (SMI) and skeletal muscle radiodensity (SMD) and selected
QoL outcomes in advanced non-small cell lung cancer (NSCLC) at diagnosis.
Methods Baseline data from patients with stage IIIB/IV NSCLC and performance status 0–2 enrolled in three randomized
trials of first-line chemotherapy (n = 1305) were analysed. Associations between SMI (cm2/m2) and SMD (Hounsfield units)
based on computed tomography-images at the third lumbar level and self-reported physical function (PF), role function
(RF), global QoL, fatigue, and dyspnoea were investigated by linear regression using flexible non-linear modelling.
Results Complete data were available for 734 patients, mean age 65 years. Mean SMI was 47.7 cm2/m2 in men (n = 420) and
39.6 cm2/m2 in women (n = 314). Low SMI values were non-linearly associated with low PF and RF (men P = 0.016/0.020,
women P = 0.004/0.012) and with low global QoL (P = 0.001) in men. Low SMI was significantly associated with high fatigue
(P = 0.002) and more pain (P = 0.015), in both genders, but not with dyspnoea. All regression analyses showed poorer physical
outcomes below an SMI breakpoint of about 42–45 cm2/m2 for men and 37–40 cm2/m2 for women. In both genders, poor PF
and more dyspnoea were significantly associated with low SMD.
Conclusions Low muscle mass in NSCLC negatively affects the patients’ PF, RF, and global QoL, possibly more so in men than
in women. However, muscle mass must be below a threshold value before this effect can be detected.
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Introduction
Lung cancer is the leading cause of cancer death worldwide,1
most patients (85%) present with non-small cell lung cancer
(NSCLC), and the majority is diagnosed with advanced
disease.2 Despite modern chemotherapy and/or novel agents
targeting genetic mutations and rearrangements,3,4 the
majority of advanced disease patients does not attain disease
control, with 5-year survival rates not exceeding 1–2%.3–5
Major treatment goals are therefore to minimize the
patients’ symptom burden and maintain functioning and
quality of life (QoL).6,7 Weight loss and malnutrition are
identified as contributors to poor QoL in NSCLC,8,9 and
weight-losing patients with inoperable NSCLC report more
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fatigue, pain, and poorer global QoL than their weight-stable
counterparts.10 Because weight loss leads to loss of lean body
mass, these findings might be directly linked to muscle waste.
Less muscle mass may influence muscle function and lead to
loss of strength, reduced pulmonary function, increased
disability, and thereby poorer QoL.11,12
Recent studies utilizing computed tomography (CT) images
to assess skeletal muscle mass have detected that muscle
wasting is a prominent feature in NSCLC even with normal
or high body mass index (BMI).13,14 Furthermore, muscle
wasting and low muscle mass have been linked to poorer
survival and increased risk of treatment toxicity in various
cancer diagnoses, including NSCLC.15–19 In advanced NSCLC,
a recent study from our group showed that low muscle mass
was a significant predictor for chemotherapy-induced
haematological toxicity.20
Increased fat content within the skeletal muscle may affect
the muscle quality and influence both muscle strength and
function.21,22 The fat content in muscle is reflected by the
skeletal muscle radiation attenuation also known as skeletal
muscle radiodensity (SMD).23 The SMD of human muscle
can be obtained by CT scans and is measured as mean
Hounsfield units (HU) of the cross-sectional muscle area.21,23
Recent studies on cancer patients have indicated that
reduced SMD is associated with poorer survival,14,24 and
former results from the present population suggested that
SMD may be a more important prognostic factor than
skeletal muscle index (SMI) in advanced NSCLC.25 Despite
the emerging evidence on the negative impact of low muscle
mass, less attention has been paid to the importance of
muscle wasting for muscle function in cancer. To our
knowledge, the direct associations between CT-based
measures of muscle mass and patient-reported outcomes
reflecting functional status have not formerly been reported
in NSCLC. This paper aims to investigate these associations
at the time of diagnosis, and we hypothesize that
pronounced low muscle mass and low SMD affect patient-
reported functional status, global QoL, dyspnoea, and fatigue
negatively and are associated with loss of appetite.
Material and methods
Patients and assessments
The study is based on three subsequent randomized
controlled trials (RCTs), conducted between 2003 and 2009,
comparing different first-line chemotherapy regimens in
advanced NSCLC.26–28 Overall survival, QoL, and toxicity were
the main endpoints, and the main inclusion criteria were
similar: chemonaïve patients, age ≥ 18 years, stage IIIB/IV,
and performance status 0–2. Median survival was not
significantly different between trial arms, in any of the RCTs
and ranged between 6.3 and 7.3 months in all trials. For
the present study, only baseline data acquired before start
of treatment were used. Complete data on relevant muscle
measures and appetite loss were required for inclusion in
the present study.
Baseline data comprised demographics, disease stage,
histology, performance status, height, weight, and QoL. QoL
was assessed using the European Organization for Research
and Treatment of Cancer Quality of Life Core Questionnaire
(QLQ)-Core 3029 and the lung cancer-specific module QLQ-
Lung Cancer 13.30 The QoL baseline assessments were
performed at inclusion, before start of chemotherapy. For
the purpose of the present study, we used the two functional
scales: physical function (PF) with five items and role function
(RF) with two items, the global QoL scale (two items), the
fatigue scale (three items), and one single item on appetite
loss. From QLQ-Lung Cancer 13, the three-item dyspnoea
scale was used as it gives a wider picture of respiratory
problems than the single dyspnoea item of the QLQ-Core
30. All items are scored on a 4-point ordinal scale, except
the two items of the global QoL scale that are scored on a
7-point scale. Before statistical analyses, the scale scores
were linearly transformed to a 0–100 scale as recommended
in the European Organization for Research and Treatment of
Cancer scoring manual.31 Higher scores on the functional and
global QoL scales represent better functioning/QoL, whereas
higher scores on fatigue, dyspnoea, and appetite loss indicate
more symptoms. Differences of 10 points or more are usually
regarded as clinically significant32 and as such perceptible to
patients.
A CT scan of the thorax/upper abdomen was performed
within 4 weeks before the baseline QoL registrations and
start of chemotherapy. The CT scans were analysed using
Slice-O-Matic software (v.4.3 Tomovision, Montreal
Canada) by three observers blinded for patient data. The
total cross-sectional areas of skeletal muscle and adipose
tissue (cm2) were quantified from images at the third
lumbar (L3) level, which is strongly correlated to the
corresponding whole body tissue masses.33 For tissue
demarcation, pre-established thresholds of HU in the range
of 29 to +150 HU for muscle tissue, 150 to 50 HU for
visceral adipose tissue, and 190 to 30 HU for sub-
cutaneous and intramuscular adipose tissue were used.34
As a measure of skeletal muscle mass, the total cross-
sectional skeletal muscle area (cm2) was normalized for
stature by dividing by squared height (m2) and expressed
as SMI (cm2/m2). SMD was measured as the mean HU of
the entire cross-sectional muscle area at L3. BMI was
calculated from the weight and height (kg/m2).
Statistics
Data from all RCTs were analysed jointly. Because of the
descriptive context, we report mean values and range.
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Independent sample t-tests were used to investigate
differences between groups on continuous variables. For
categorical variables, Pearson’s chi-squared tests were
applied.
Because of gender differences in muscle mass, the
association to baseline QoL parameters were analysed
separately for men and women. SMI was defined as the
explanatory variable for muscle mass. The association
between SMI and the defined outcomes was investigated
by linear regression using flexible non-linear modelling with
restricted cubic splines35,36 and likewise the association
between SMD and the defined outcomes.
Using restricted cubic splines, no assumption of the
specific form of the relationship is needed. It means that
the independent variable is transformed into segments,
defined by knots allowing for smoothly fitted curves for each
segment. The procedure includes formal tests of linearity in
the relationships and allows for flexible descriptions of non-
linearity. The increase of degrees of freedom is moderate.
Modelling using restricted cubic splines is available in
commonly used regression models including linear, logistic,
and Cox regression. The main analyses were unadjusted,
and in addition, sensitivity to adjustment for age and stage
was investigated as these variables were judged to be the
most relevant, possible confounding factors.
Being assessed by a single item, the scores for appetite loss
had only four possible response categories. Thus, the linear
regression method applied for the other QoL parameters
was not suitable to investigate the association between the
muscle measures and this symptom. Hence, to explore a
possible relationship, mean SMI and mean SMD were
compared between patients reporting no appetite loss and
those who indicated having either ‘a little’, ‘quite a bit’, or
‘very much’.
All P-values were two-sided, and values <0.05 defined
statistical significance. Analyses were performed using R
(The R foundation for statistical computing, Vienna, Austria)
with the R package rms for flexible non-linear modelling
and with IBM SPSS v.18 (Armonk, NY, USA).
Ethics
The study was performed according to the Helsinki
declaration and approved by the Regional Committee for
Medical Research Ethics South-East.
Results
Study population and general characteristics
A total of 1305 patients were included in the RCTs. Baseline
CT scans were collected from 1119 patients (86%). Because
of lack of images at the L3-level or poor image quality, only
771 patients were available for quantification of muscle
mass. Another 37 patients were excluded because of
missing data on height, appetite loss, or SMD, leaving 734
patients for the present analyses. Most missing CT scans
were from the earliest study (RCT 1, n = 174) as they were
stored on film and not analysable. The final sample of the
present study included 420 men (57%) and 314 women
(43%) with a mean age of 66.5 and 63.7 years, respectively.
The included patients comprised a lower proportion of stage
IIIB and a higher proportion of performance status one than
the excluded. Otherwise, the two cohorts were comparable.
The distribution of chemotherapy regimens and baseline
characteristics were also comparable between genders. A
full description of the selection of patients, the study
population, and the excluded patients has been presented
earlier.25
Body composition
The mean BMI of both genders was within the normal range
(Table 1). Overall, a BMI below 20 (underweight) was found
in 18% of our patients, while 5% presented with a BMI ≥ 30
(obesity). The muscle measures varied largely, but the
variables did not deviate substantially from normal
distributions. The mean skeletal muscle area was 148.8 cm2
(SD 23.8) in men and 107.3 cm2 (SD 16.3) in women
(P < 0.001), and the SMI was 47.7 cm2/m2 (SD 7.6, range
27.9–74.5) and 39.6 cm2/m2 (SD 5.7, range 26.1–54.6)
(P < 0.001) in men and women, respectively. The mean
SMD was 37.4 HU (SD 8.1, range 15.8–60.4) in men and
37.0 HU (SD 9.0, range 14.8–62.3) in women (ns). A detailed
description of how SMI and SMD differed according to stage
of disease, age, and performance status for each gender
separately is to be found in a supplementary table
(Supplementary Information, Table S1).
Quality of life and association to muscle
measurements
The patients’ baseline QoL data are presented in Table 2.
There were statistically significant differences between men
and women for global QoL and fatigue. None of these
differences exceeded 10 points, and they were all in favour
of better scores among men. Appetite loss was reported by
224 (53.3%) men and 178 (56.7%) women.
Diagrams illustrating the associations between SMI and
PF, RF and global QoL including 95% confidence intervals
are displayed in Figure 1. For both genders, the regression
analyses showed significant non-linear associations between
SMI and PF (men: P = 0.016, women: P = 0.004), and
between SMI and RF (men: P = 0.020, women: P = 0.012).
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For global QoL, there was a significant association to SMI
only for men (P = 0.001). Below a breakpoint at about
42–45 cm2/m2 for men and 37–40 cm2/m2 for women,
the patients’ scores deteriorated with decreasing SMI. SMI
values above this breakpoint were associated with relatively
stable PF and RF scores. Fatigue (Figure 2) varied
significantly with SMI but only in the male population
(P = 0.002). The associations between SMI and dyspnoea
were insignificant for both genders (P ≥ 0.493). All
regression curves had breakpoints corresponding to those
observed for PF and RF, below which the reported symptom
level rapidly increased with decreasing SMI. Adjustment for
age and stage of disease did not substantially change the
slopes of any of the regression curves, and the breakpoints
generally corresponded to those found in the unadjusted
analyses. Furthermore, the associations that were significant
in the unadjusted analyses were also significant in adjusted
analyses.
Men who reported appetite loss had a significantly lower
SMI (46.6 cm2/m2) compared with those who did not
(48.8 cm2/m2) (P = 0.003). For women, there was a trend in
the same direction. SMI was 39.1 cm2/m2 and 40.3 cm2/m2
among women with and without appetite loss, respectively
(P = 0.058).
For both genders, the regression analyses showed
significant associations between SMD and PF (men:
P = 0.015, women: P < 0.001) and between SMD and
dyspnoea (men: P = 0.002, women: P = 0.01). These
associations were not significantly non-linear, but a trend of
patterns with a breakpoint as for the associations between
SMI and the QoL variables was seen. This breakpoint was
similar for men and women, around 32–34 HU. Adjusted for
age and stage of disease, the slopes and the corresponding
breakpoints remained visually similar. SMD and dyspnoea
were also still significantly associated (men: P = 0.005,
women P = 0.029), whereas the association between SMD
and PF was significant for women only (men: P = 0.053,
women: P = 0.002). In the unadjusted analysis, SMD was also
significantly associated to fatigue among men (P = 0.041), and
the association was significantly non-linear (P = 0.028). With
adjustment for age and stage of disease, the association
was no longer significant (P = 0.066), but the association
was significantly non-linear (P = 0.035).
Table 2 Baseline scores on the quality of life scales hypothesized to be
affected by muscle wasting and low muscle radiation attenuation, all
patients and according to gender
Quality of life scores
All patients Men Women
Mean SD Mean Mean P
QLQ-C30
Physical function 64.3 +/24.0 65.6 62.4 0.080
Role function 51.5 +/35.0 51.5 51.4 0.950
Global QoL 52.7 +/24.6 55.0 49.7 0.004
Fatigue 47.7 +/27.3 46.0 50.0 0.047
Appetite loss 33.4 +/36.3 32.1 35.2 0.240
LC-13
Dyspnoea 38.7 +/26.3 38.7 38.6 0.979
QoL, quality of life; SD, standard deviation; QLQ-C30, Quality of
Life Questionnaire-Core 30; LC-13, Lung Cancer-13.
Table 1 Baseline patient characteristics
Patients
All Men Women
n = 734 n = 420 n = 314
(100%) (57.2%) (42.8%)
Age, years, mean (SD) 65.4 (9.4) 66.5 (8.8) 63.7 (9.8)
Follow-up, months, median (SD) 7.2 (7.5) 6.4 (7.1) 8.0 (8.0)
n % n % n %
Age ≥ 75 132 18.0 80 19.0 52 16.6
Histology
Squamous 171 23.3 122 29.0 49 15.6
Adenocarcinoma 388 52.9 197 46.9 191 60.8
Large cell 46 6.3 23 5.5 23 7.3
Other 129 17.6 78 18.6 51 16.2
Disease stage
Stage IIIB 152 20.7 83 19.8 69 22.0
Stage IV 582 79.3 337 80.2 245 78.0
Performance status (PS)
PS 0 165 22.5 98 23.3 67 21.3
PS 1 404 55.0 226 53.8 178 56.7
PS 2 165 22.5 96 22.9 69 22.0
Study
RCT 1 153 20.8 93 22.1 60 19.1
RCT 2 266 36.2 153 36.4 113 36.0
RCT 3 315 42.9 174 41.4 141 44.9
BMI, kg/m2, mean (SD) 23.4 (3.9) 23.5 (3.6) 23.4 (4.3)
BMI, body mass index; RCT, randomized controlled trial; SD, standard deviation.
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Discussion
This study provides new findings regarding the relationship
between low muscle mass in cancer and QoL. We found that
low muscle mass (expressed as SMI) was significantly
non-linearly associated with self-reported functional
deterioration in advanced NSCLC patients of both genders
also when adjusted for age and stage of disease. In our male
cohort, low SMI was also significantly associated with poor
global QoL and high intensity of fatigue but did not show
significant non-linearity. SMD, which gives an indication of
fat infiltration in muscle that may affect both muscle strength
Figure 1 The relation between the third lumbar (L3) skeletal muscle index (cm2/m2) and physical function, role function, and global quality of life
(QoL).
Figure 2 The relation between the third lumbar (L3) skeletal muscle index (cm2/m2) and fatigue and dyspnoea.
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and function,23,21 was significantly associated with PF and
dyspnoea for both genders. However, adjusted analyses
demonstrated no significant association with PF in the male
cohort but a significant association to fatigue.
In the present study, muscle assessments were performed
with a well-established radiological method,14 and we used
widely accepted attenuation ranges for the demarcation of
muscle area (29 to +150 HU).23 To assess QoL, validated
and widely used questionnaires were applied, and the results
are based on data from a large, disease-specific, relatively
homogeneous cohort with advanced NSCLC. All patients were
enrolled in nationwide RCTs according to similar criteria, and
all assessments were obtained before start of treatment. A
primary study limitation was that muscle measures could
not be obtained for a substantial proportion of the targeted
population. The exclusion of patients from the original
cohorts was, however, mainly due to technicalities, and we
therefore believe that our findings are representative for
NSCLC patients eligible for first-line palliative chemotherapy.
Because the RCTs were not designed for the present purpose
and the cross-sectional design, data on weight loss and
comorbidity were not available for all patients, and we do
not know if the muscle loss was recent or not. Thus, we
cannot rule out that the influence of low muscle mass on
QoL may differ according to aetiology and rate of
development.
To the best of our knowledge, only one study has
performed analyses that are somewhat similar to ours in a
cancer population. In this study of a variety of advanced
cancers, there were no statistically significant associations
between SMI and dyspnoea, fatigue, or appetite loss.37
However, the results from our cohort visually indicated that
muscular mass had to fall below a certain value before a
negative impact on physical function and the other QoL
scores could be detected. A corresponding trend was found
for SMD. Declining physical function and performance has
traditionally been attributed to decreased muscle mass,
but our results indicate that modest reductions in skeletal
muscle mass, as measured by SMI, may not affect function.
This is in line with emerging evidence from non-cancer
populations showing similar non-linear relationships
between muscle mass and functional status. In elderly
patients, it is demonstrated that muscle waste has to
progress to a point below 30% of the mean of young adults
before decrease in functional abilities are observed.38,21 It
has also been shown that physical performance is not solely
dependent on muscle mass but also muscle strength.22,39
Muscle strength, in turn, is reported to be independently
associated with muscle radiodensity,40 and in accordance
with our findings, greater muscular fat infiltration is found
to increase the risk of immobility in older men and
women.41
Former studies in cancer patients have mainly linked low
muscle mass to increased morbidity and mortality.15,16,19,34,38
Our study indicates that skeletal muscle mass below formerly
reported threshold values (male, SMI < 43 cm2/m2 when
BMI <25 and female, SMI < 41 cm2/m2 for all BMI groups)14
is also associated with low physical function and probably
affects global QoL. Similar findings have been found in
connection with chronic heart failure.39 As low SMI appears
to be a benchmark for higher morbidity and mortality, low
physical functioning and QOL, maintaining patients above
these threshold values could potentially be associated with
important clinical benefit. Treatments that will enhance
muscle mass or at least slow its depletion, improve strength,
and enhance the capacity for independent functioning are
therefore needed. Nutritional supplements that are able to
generate an anabolic response40 and drugs, for example
Anamorelin,41 have demonstrated effects in the prevention
and treatment of muscle loss in NSCLC. In future studies, it
would be of interest to further investigate these effects as
well as combine them with physical activity. It has already
been demonstrated that physical activity may enhance
muscle mass or at least slow its depletion, improve strength,
and enhance the capacity for independent functioning in
advanced stages of cancer.42
Our findings indicate a difference between men and
women regarding the impact of muscular depletion on global
QoL and fatigue. An explanation may be that both global QoL
and fatigue are measures that are likely to be influenced by
several factors other than muscular depletion and functional
ability.
In contrast to our hypothesis, we did not detect a
significant association between SMI and dyspnoea.
Accordingly, no beneficial effects of muscle mass on lung
function have been demonstrated in studies of chronic
pulmonary disease,43,44 indicating that in lung diseases, the
disease itself may be more important for the respiratory
function than skeletal muscle waste. Still, the regression
curves for SMI and dyspnoea showed a similar pattern as
the curves for physical and RF, possibly indicating a point
below which muscle waste affects dyspnoea. The significant
association between SMD and dyspnoea may support this
assumption. As documented in geriatric patients, elevated
fat content in the skeletal muscle may affect muscle strength
more than plain muscle waste.22,21
Loss of appetite is one of the most prevalent symptoms in
advanced cancer and considered an important component of
cancer cachexia.45 Both the female and male patients in this
study reported average scores above 30 on appetite loss,
which is significantly higher than scores seen in the general
population.46 We found significant associations between
SMI and poor appetite, which may indicate that reduced food
intake may have affected the ability to preserve muscle
mass.45 Normally, loss of weight includes muscle loss and
evolves from decreased food intake. However, many patients
with NSCLC lose more weight than expected from an
estimated energy deficit.47–49 This may indicate the presence
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of cancer cachexia where loss of skeletal muscle mass is
considered to be driven by metabolic alterations.49 Whether
low muscle mass in this study was related to undernutrition,
cancer cachexia, comorbid conditions, or a combination of
these cannot be determined from the available data. Thus,
the impact of these factors should be further investigated
in larger prospective studies.
In conclusion, pronounced low skeletal muscle mass in
patients with NSCLC seemed to affect functional status and
global health negatively. Our data indicate that these effects
occur when muscle mass falls below a breakpoint quite
similar to the threshold values formerly found to be
associated with increased mortality.34,38 Our findings show
the importance of connecting CT derived body composition
to meaningful patient-centred outcomes. Further studies
are warranted both to confirm these findings and to
determine the importance of weight loss and cachexia for
QoL in cancer patients.
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